The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date ...
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...
The FDA has accepted the application for belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...
Eleven studies describing sinoatrial (SA) nodal, atrioventricular (AV) nodal or infra-Hisian conduction parameters in the setting of cocaine use were found. Fourteen studies and two case series ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback